ISPAD Clinical Practice Consensus Guidelines 2024 : Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes
(2025) In Hormone Research in Paediatrics 97(6). p.529-545- Abstract
The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This guideline serves as an update to the 2022 ISPAD consensus guideline on staging for type 1 diabetes (T1D). Key additions include an evidence-based summary of recommendations for screening for risk of T1D and monitoring those with early-stage T1D. In addition, a review of clinical trials designed to delay progression to Stage 3 T1D and efforts seeking to preserve beta-cell function in those with Stage 3 T1D are included. Lastly, opportunities and challenges associated with the... (More)
The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This guideline serves as an update to the 2022 ISPAD consensus guideline on staging for type 1 diabetes (T1D). Key additions include an evidence-based summary of recommendations for screening for risk of T1D and monitoring those with early-stage T1D. In addition, a review of clinical trials designed to delay progression to Stage 3 T1D and efforts seeking to preserve beta-cell function in those with Stage 3 T1D are included. Lastly, opportunities and challenges associated with the recent US Food and Drug Administration (FDA) approval of teplizumab as an immunotherapy to delay progression are discussed. The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This guideline serves as an update to the 2022 ISPAD consensus guideline on staging for type 1 diabetes (T1D). Key additions include an evidence-based summary of recommendations for screening for risk of T1D and monitoring those with early-stage T1D. In addition, a review of clinical trials designed to delay progression to Stage 3 T1D and efforts seeking to preserve beta-cell function in those with Stage 3 T1D are included. Lastly, opportunities and challenges associated with the recent US Food and Drug Administration (FDA) approval of teplizumab as an immunotherapy to delay progression are discussed.
(Less)
- author
- organization
- publishing date
- 2025
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Humans, Diabetes Mellitus, Type 1/therapy, Adolescent, Child, Insulin-Secreting Cells/pathology, Female, Societies, Medical/standards, Male
- in
- Hormone Research in Paediatrics
- volume
- 97
- issue
- 6
- pages
- 17 pages
- publisher
- Karger
- external identifiers
-
- scopus:85217152332
- pmid:39662065
- ISSN
- 1663-2826
- DOI
- 10.1159/000543035
- language
- English
- LU publication?
- yes
- additional info
- © 2024 The Author(s). Published by S. Karger AG, Basel.
- id
- fe45c69c-612b-419c-9a71-33965ab65dff
- date added to LUP
- 2025-02-27 11:53:20
- date last changed
- 2025-05-23 11:37:39
@article{fe45c69c-612b-419c-9a71-33965ab65dff, abstract = {{<p>The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This guideline serves as an update to the 2022 ISPAD consensus guideline on staging for type 1 diabetes (T1D). Key additions include an evidence-based summary of recommendations for screening for risk of T1D and monitoring those with early-stage T1D. In addition, a review of clinical trials designed to delay progression to Stage 3 T1D and efforts seeking to preserve beta-cell function in those with Stage 3 T1D are included. Lastly, opportunities and challenges associated with the recent US Food and Drug Administration (FDA) approval of teplizumab as an immunotherapy to delay progression are discussed. The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This guideline serves as an update to the 2022 ISPAD consensus guideline on staging for type 1 diabetes (T1D). Key additions include an evidence-based summary of recommendations for screening for risk of T1D and monitoring those with early-stage T1D. In addition, a review of clinical trials designed to delay progression to Stage 3 T1D and efforts seeking to preserve beta-cell function in those with Stage 3 T1D are included. Lastly, opportunities and challenges associated with the recent US Food and Drug Administration (FDA) approval of teplizumab as an immunotherapy to delay progression are discussed.</p>}}, author = {{Haller, Michael J and Bell, Kirstine J and Besser, Rachel E J and Casteels, Kristina and Couper, Jenny J and Craig, Maria E and Elding Larsson, Helena and Jacobsen, Laura and Lange, Karin and Oron, Tal and Sims, Emily K and Speake, Cate and Tosur, Mustafa and Ulivi, Francesca and Ziegler, Anette-G and Wherrett, Diane K and Marcovecchio, M Loredana}}, issn = {{1663-2826}}, keywords = {{Humans; Diabetes Mellitus, Type 1/therapy; Adolescent; Child; Insulin-Secreting Cells/pathology; Female; Societies, Medical/standards; Male}}, language = {{eng}}, number = {{6}}, pages = {{529--545}}, publisher = {{Karger}}, series = {{Hormone Research in Paediatrics}}, title = {{ISPAD Clinical Practice Consensus Guidelines 2024 : Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes}}, url = {{http://dx.doi.org/10.1159/000543035}}, doi = {{10.1159/000543035}}, volume = {{97}}, year = {{2025}}, }